Quantumzyme Corp., a biotechnology company specializing in computational enzyme engineering, is working diligently to address concerns raised by OTC Markets Group regarding its securities designation and unauthorized promotional activities.
The company has immediately initiated contact with OTC Markets to understand and resolve the reasons behind the Caveat Emptor status. CEO Naveen Kulkarni stated that the organization is committed to a swift and cooperative resolution, and has retained legal counsel to support the process.
Quantumzyme categorically denied any involvement with recent promotional SMS text messages that mentioned the company. The firm emphasized that it did not authorize, endorse, or have prior knowledge of these communications and condemned such unauthorized promotional efforts.
The company's proactive approach underscores its dedication to maintaining regulatory compliance and market integrity. By addressing these issues transparently and promptly, Quantumzyme aims to protect its reputation and ensure accurate communication with shareholders and market participants.
As the situation develops, Quantumzyme remains focused on its core business strategy of delivering sustainable, enzyme-based solutions through advanced computational and AI-driven technologies.
